Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of costs proposal.

被引：0
|
作者：
Guirgis, Helmy M. [1 ]
机构：
[1] Canc Free Fdn, Dana Point, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21738
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TREATMENT PATTERNS, SURVIVAL, AND MEDICARE SPENDING FOR ADVANCED LUNG CANCER IN THE ERA OF IMMUNE CHECKPOINT INHIBITORS
    Youn, B.
    Wilson, I. B.
    Mor, V
    Trikalinos, N.
    Dahabreh, I. J.
    VALUE IN HEALTH, 2020, 23 : S61 - S61
  • [42] Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis
    Cantini, Luca
    Merloni, Filippo
    Rinaldi, Silvia
    Lenci, Edoardo
    Marcantognini, Giulia
    Meletani, Tania
    Fiordoliva, Ilaria
    Morgese, Francesca
    Torniai, Mariangela
    Ricci, Giulia
    Giampieri, Riccardo
    Berardi, Rossana
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 151
  • [43] Patterns of treatment with immune check point inhibitors and targeted therapy in patients with metastatic melanoma presumed BRAF V600 positive
    Ghate, Sameer
    Nakasato, Antonio
    Ionescu-Ittu, Raluca
    Shi, Sherry
    Ndife, Briana
    Burne, Rebecca
    Laliberte, Francois
    Duh, Mei Sheng
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Reduced risk of secondary primary extra pulmonary cancer in advanced/ metastatic lung cancer patients treated with immune checkpoint inhibitors
    Heudel, P. E.
    de Montfort, A.
    Debieuvre, D.
    Chouaid, C.
    Carton, M.
    Audigier-Valette, C.
    Filleron, T.
    Chabaud, S.
    Stancu, A.
    Quantin, X.
    Hiret, S.
    Bosquet, L.
    Blay, J. Y.
    LUNG CANCER, 2023, 182
  • [45] Immune checkpoint inhibitors in the first-line treatment of metastatic small-cell lung cancer
    Knetki-Wroblewska, Magdalena
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (02): : 104 - 114
  • [46] Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type
    Vadagam, Pratyusha
    Waters, Dexter
    Lee, Inyoung
    Chen, Justin
    Tian, Dajun
    Near, Aimee M.
    Lyle, Derek
    Vanderpoel, Julie
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 219 - 229
  • [47] Current strategies incorporating immune checkpoint inhibitors for the treatment of advanced or metastatic non-small-cell lung cancers
    Motta, Gianmarco
    Vigneri, Paolo
    FUTURE ONCOLOGY, 2019, 15 (27) : 3097 - 3101
  • [48] Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors
    Drommi, Fabiana
    Calabro, Alessia
    Vento, Grazia
    Pezzino, Gaetana
    Cavaliere, Riccardo
    Omero, Fausto
    Muscolino, Paola
    Granata, Barbara
    D'Anna, Federica
    Silvestris, Nicola
    De Pasquale, Claudia
    Ferlazzo, Guido
    Campana, Stefania
    CANCERS, 2023, 15 (11)
  • [49] The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
    Lee, June-Koo
    Kim, Dong-Wan
    Keam, Bhumsuk
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Young-Joo
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 182 - 188
  • [50] Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020
    Norgaard, Mette
    Mailhac, Aurelie
    Fagerlund, Karin
    Strunz-McKendry, Torsten
    Agerbaek, Mads
    Jensen, Jorgen Bjerggaard
    ACTA ONCOLOGICA, 2023, 62 (12) : 1784 - 1790
12345